이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

To Identify if a COPD Self-management App Can Safety and Appropriately Identify When Patients Are Not on the Best Medication Plan for Their COPD Symptoms and Support Their COPD Management. (mySmartCOPD)

2026년 8월 28일 업데이트: University of Southampton

To Explore the Safety and Clinical Efficacy of a Treatment Realignment Algorithm Using Data From a Digital Self-management Application for Patients With COPD

Although COPD cannot be cured, managing COPD can help reduce symptoms control, slows progression of the disease, and may improve the quality of life. Management of COPD becomes less effective when healthcare professionals fail to prescribe appropriate inhaled therapies, due to poor adherence to evidence-based guidelines and underdiagnosis, or when patients fail to adhere to prescribed treatment regimens.

my mhealth has developed an app called myCOPD to allow patients to record their COPD symptoms and medications, which in term supports them with their COPD. This app is now used by COPD patients across the UK, via a prescription from their healthcare professionals. my mHealth has now developed a research app MMH-LAB1 which, in the intervention arm, includes an algorithm to assist patients with understanding their level of symptom burden according to the severity of their daily symptoms and exacerbation risk. The algorithm then analyses current patient prescribed inhaled medication against those recommended by the GOLD 2023 report and informs the patient via the MMH-LAB1 app as to whether their medication needs to be changed by their healthcare provider. This trial will explore whether the introduction of the algorithm within the MMH-LAB1 app can be used as a safe, effective and acceptable tool to assist patients to achieve optimal guideline based inhaled therapy and therefore provide greater symptom control and lowered exacerbation risk for COPD patients.

Participants will be randomised to the MMH-LAB1 app - control arm (MMH-LAB_Control_1 where participants just record COPD symptoms and medications), or to the MMH_LAB1 app - intervention arm (MMH-LAB1_Test_1 where participants record their COPD symptoms and medication plus receiving information from the algorithm, as to whether their medications are in guidance or not, and if not, be notified to visit their healthcare professional.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

This study is an open-label randomised control trial with inbuilt pilot phase and qualitative sub-study:

Phase 1 (pilot - 50 participants): Interim futility analysis on adherence to intervention advice Phase 2 (efficacy - 746 participants (including pilot phase participants): Safety acceptability and efficacy of intervention. This includes the qualitative sub study 15-20 participants (from the 746 Phase 2 participants).

Qualitative Sub-study: Acceptability of the intervention (15-20 intervention participants)

This trial will explore whether the introduction of the treatment realignment algorithm can be used as a safe, effective and acceptable tool to assist patients to achieve optimal, guideline based inhaled therapy and therefore provide greater symptom control and lowered exacerbation risk for COPD patients. To assess effect of the intervention on patients' symptom control, including exacerbation frequency and patient wellness scores.

Main objectives

  • To understand the intervention pathway in the pilot phase and to identify additional patient support mechanisms for the efficacy phase in order to maximise healthcare equality
  • To assess the levels of app usage and engagement
  • To assess patients' experience of using the intervention

Study Design:

Open-Label Randomised Control Trial with inbuilt pilot phase Qualitative Sub study:

Phase 1 (Pilot): Interim futility analysis on adherence to intervention advice Phase 2 (Efficacy): Safety, acceptability and efficacy of intervention Qualitative Sub-study: Acceptability of the intervention.

The research question is to explore the safety and efficacy of the treatment re-alignment algorithm as part of a digital self-management application (app) in patients with COPD.

연구 유형

중재적

등록 (추정된)

746

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • England
      • Southampton, England, 영국, SO16 6YD
        • 모병
        • University Hospital Southampton
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

예

설명

Inclusion Criteria:

  1. Adult patients over 18 years of age and able to give informed consent
  2. A clinical diagnosis of COPD (all patients registered on the app have a confirmed diagnosis of COPD confirmed by their clinician before being prescribed the app).
  3. A registered and activated user of the myCOPD app
  4. One or more CAT questionnaire completed on the myCOPD app in the last 12 months
  5. One or more exacerbation form completed on the myCOPD app in the last 12 months CTU/FORM/5321 - CIP template for Clinical Investigations of Medical Devices, Version 1 14-DEC-2023 mySmartCOPD Clinical Investigation Plan v1 25-FEB-2025 Page 25 of 53
  6. One or more COPD medication diary completed on the myCOPD app in the last 12 months
  7. Classified appropriately into 3 groups:

    (A) Few symptoms (CAT <10, 0 or 1 moderate exacerbations) (B) Many symptoms (CAT ≥10, ≥0 or 1 moderate exacerbations) (C)Exacerbators (≥2 moderate or ≥1 severe exacerbation independent of CAT)

    Exclusion Criteria:

  8. Cannot read or write in English as required to understand the trial materials and provide the trial data.
  9. Has not opted in to the research agreement via MyCOPD

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 지지 요법
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: MMH-LAB1 Control This arm is based on the original COPD app the participants already use
Participants for this study are already users of a COPD self management app. This arm is a replica of this app, with additional questionnaires built in
This app is based on a COPD self management app, which they are already using and includes an algorithm which will notify participants if there is a discrepancy between the symptoms they report onto the app and their medication regime, and informs them to approach their healthcare provider for a medication review
실험적: MMH-LAB1 Test This arm is based on the original COPD app the participants use plus an algorithm
Participants for this study are already users of a COPD self management app. This arm is a replica of this app, with additional questionnaires built in plus an algorithm which identifies, based on the symptoms and medication reported onto the app by the participant, whether they are on the correct medication or not. If not, the app will generate a notification and inform the participant that they need to approach their healthcare provider and inform them of this and that they need a medication review.
This app is based on a COPD self management app, which they are already using and includes an algorithm which will notify participants if there is a discrepancy between the symptoms they report onto the app and their medication regime, and informs them to approach their healthcare provider for a medication review

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
To determine the safety, acceptability and efficacy of a digital treatment guidance algorithm for inhaled treatment in patients with COPD. The intention is to measure the impact of the algorithm in prompting patients to achieve optimal management, and t
기간: 6 months
Proportion (measured in %) of participants receiving guideline adherent treatment at Baseline and trial completion (Month 6). Range 0%-100%.
6 months

2차 결과 측정

결과 측정
측정값 설명
기간
To assess effect of intervention on exacerbation frequency and patient wellness scores
기간: 6 months

• Change in COPD Assessment Test (CAT) score between Baseline and trial completion (Month 6)

CAT test results 0 minimal symptom impact - Best and 40 maximum symptom impact

All will be described in terms of:

  • Mean and SD
  • Median and range and will be reported as descriptive stats
6 months
To assess effect of the intervention on patients' adherence to guideline mandated treatment
기간: 6 months

- Rate of indication of algorithm to change treatment (0 times to 150 times)

• Rate if change in response to treatment change indication (0 times to 150 times)

All measured via frequency and percentage and description of change.

The combination of measurements will be reported as descriptive stats

6 months
To understand the utility of the intervention pathway in the pilot phase and to identify additional patient support mechanisms for the efficacy phase in order to maximise healthcare equality
기간: 6 months

- % Patients receiving guideline adherent treatment at Baseline and trial completion (Month 6). 100% good. 0 % bad.

Above described qualitatively and in terms of % and frequency

6 months
To assess the levels of app algorithm usage and engagement
기간: 6 months

-Frequency of app engagement

  • Rate of completion of endpoint data
  • Resource requirement to allow patients to act on intervention information

Measured by frequency (numbers of participant who completed everything) % (0% of expected use bad and 100% of expected use good). This will be reported as descriptive stats.

6 months
To understand patients' experience of using the intervention
기간: 3-6 months - interviews. 6 months - feedback questionnaire

This section relates to the qualitative sub-study and will look at the following:

- Patient experience and patient and patient advocate feedback on experience of using app

• Patient satisfaction Rating using the Patient

Using feedback questionnaire at month 6 and qualitative interviews as part of the sub -study

  • Qualitative data will be thematically analysed and written up in a report. Tables will be produced outlining key themes and illustrative quotes
  • Frequency and percentage.
  • Means and standard deviations.
  • Statistical tests may be performed to explore any difference in experience of using the intervention relative to cohort groupings

This will be reported in a separate analysis document using qualitative research analysis and reporting techniques and norms

3-6 months - interviews. 6 months - feedback questionnaire
To assess the safety of the algorithm
기간: 6 months

• Rate of algorithm inappropriately firing notifications

This is data collected via MMHLAB apps and qualitatively via patient advocate.

  • Frequency and percentage. (0 times good, not maximum time - But anything over 0 is bad)
  • Means and standard deviations.
6 months
To assess the change in frequency of exacerbations
기간: 6 months
Frequency of exacerbation between Baseline and trial completion (Month 6) • Frequency and percentages (for number of exacerbations) Frequency will be measured from 0-150 with 0 being optimal. This will be reported as descriptive stats.
6 months
To assess the change in Quality of Life between baseline and 6 months
기간: 6 months
Change in Quality of Life. Ratings measured using EQ-5D questionnaire between Baseline and trial completion (Month 6). All will be described in terms of: • Mean and SD • Median and range. Score 11111 will be classed as full health and 55555 will be classed worst health. This will be reported as descriptive stats
6 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 10월 8일

기본 완료 (추정된)

2026년 9월 1일

연구 완료 (추정된)

2026년 9월 1일

연구 등록 날짜

최초 제출

2025년 5월 7일

QC 기준을 충족하는 최초 제출

2026년 8월 28일

처음 게시됨 (실제)

2026년 9월 1일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 28일

마지막으로 확인됨

2026년 5월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • 355764
  • AI_Award02200 (기타 보조금/기금 번호: UK - National Institute for Health and Care Research)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다